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Ubiquitination, the covalent attachment of ubiquitin molecules to proteins, is emerging as a widely utilized
mechanism for rapidly regulating cell signaling. Recent studies indicate that ubiquitination plays potent roles
in regulating a variety of signals in both innate and adaptive immune cells. Here, we will review recent studies
of ubiquitin ligases, ubiquitin chain linkages, and ubiquitin binding proteins that highlight the diversity and
specificity of ubiquitin dependent functions in immune cells. We will also review studies that shed light on
how ubiquitination signals are integrated in cell-type-specific fashion to regulate the immune system in vivo.The Ubiquitin System
The regulation of intracellular signals allows immune cells to inte-
grate stimuli from their environment and to exhibit the dynamic
plasticity characteristic of immune responses. The transduction
of such signals requires rapid posttranslational modifications
of proteins via processes such as phosphorylation or ubiquitina-
tion. While phosphorylation events are generally binary, com-
prising the presence or absence of a single phosphate group
on selected amino acids of target proteins (e.g., serine, threo-
nine, or tyrosine), ubiquitination events include the attachment
of a variety of lengths and conformations of ubiquitin chains,
mostly on lysine residues (Pickart and Fushman, 2004). Under-
standing how ubiquitination events are regulated, and how
they regulate a diverse array of cellular responses (Table 1),
requires an understanding of the components of the ubiquitin
system.
Ubiquitination involves a three-step enzymatic reaction cata-
lyzed by three different types of proteins, termed E1, E2, and
E3 ubiquitin ligases (Pickart and Eddins, 2004). An E1 enzyme
first ‘‘activates’’ ubiquitin by forming a thiol ester bond. Acti-
vated ubiquitin is transferred to an E2 ubiquitin-conjugating
enzyme. The E2 enzyme-ubiquitin complex interacts with an
E3 ubiquitin ligase that facilitates transfer of the ubiquitin to
the epsilon-amino group of a lysine (K) on substrate proteins.
Together with ubiquitin binding proteins (or sensors) and prote-
ases that function as deubiquitinating enzymes (DUBs), E1, E2,
and E3 ubiquitin ligase complexes constitute the core biochem-
ical machinery for building, editing, and removing ubiquitin
chains.
While two known E1 enzymes ‘‘charge’’ or activate ubiquitin
molecules for virtually all ubiquitination events in the mammalian
proteome, diverse combinations of E2 and E3 ubiquitin ligases
attach distinct types of ubiquitin chains to specific substrate
proteins. Approximately 38 E2 enzymes are predicted to exist
(Ye andRape, 2009). As there aremanymore E3 ubiquitin ligases
(>600 predicted) than E2s, most E2s functionally interact with
many E3 ubiquitin ligases. In addition, at least some E3s can
bind to multiple E2s. For example, the E3 ubiquitin ligase
complex of BRCA1 and BARD1 can interact with ten different
E2s that display divergent functions; one E2 may mediate ubiq-
uitin initiation and other E2s may mediate the elongation of
various linkages depending on the E2 used (Christensen et al.,2007; Christensen and Klevit, 2009). Hence, a vast number of
E2 and E3 combinations are available to specify the target
proteins to be modified and the type of ubiquitin chains to be
added.
E2 enzymes play a major role in determining the length and
linkage type of ubiquitin chains that are formed (Christensen
and Klevit, 2009; Ye and Rape, 2009). For example, the E2
enzyme Ubc13 preferentially builds K63-linked ubiquitin chains
that support mitogen-activated protein (MAP) kinase signal
propagation (Yamamoto et al., 2006a, Rodrigo-Brenni et al.,
2010; David et al., 2010). Ubc13 is required for interleukin-1
(IL-1) and lipopolysaccharide (LPS)-induced MAP kinase activa-
tion but appears less important for Nuclear Factor-kB (NF-kB)
signaling from these ligands in macrophages and fibroblasts
(Yamamoto et al., 2006a). Ubc13 also appears to be dispens-
able for tumor necrosis factor (TNF)-induced NF-kB signaling.
In contrast, Ubc13 is important for T cell receptor (TCR)-induced
NF-kB signaling in thymocytes (Yamamoto et al., 2006b). It is
possible that other E2 ligases, such as Ubc5, can support K63
ubiquitin-dependent signals, depending on the cell type and
stimulus. The selectivity of E2s for certain subsets of E3
enzymes (and hence substrates) and the predilection of E2s to
form particular ubiquitin chain linkages combine to render these
enzymes important regulators as well as mediators of ubiquiti-
nation.
E3 ubiquitin ligases confer substrate specificity to the ubiquitin
reaction by binding to and mediating transfer of ubiquitin from
E2 enzymes to target proteins such as signaling molecules. E3
ubiquitin ligases have been divided into two general types
depending on the type of protein domain used to recognize
substrates: really interesting new gene (RING) and homologous
to E6-associated protein carboxyl terminus (HECT) E3 ubiquitin
ligases. RING E3s make up the largest number by far, with
over 600 predicted to be encoded in the human genome, while
28 HECT E3s are predicted to exist (Deshaies and Joazeiro,
2009; Rotin and Kumar, 2009).
RING and HECT E3s mediate substrate ubiquitination by
different mechanisms. RING E3s use their RING finger domain
to direct the transfer of ubiquitin from the activated E2-Ub to
the substrate, whereas HECT E3s accept the ubiquitin from the
E2-Ub to form a covalent thioester bond intermediate before
transferring ubiquitin to the target protein. Because HECT E3sImmunity 33, December 22, 2010 ª2010 Elsevier Inc. 843
Table 1. E3 Ubiquitin Ligases Are Integral Mediators of Immune Regulation
Immune
Cell Type
E3 Ubiquitin
Ligase Function References
T Cells
TRAF6 TCR signaling, central T cell tolerance King et al., 2006, 2008; Lin and Mak, 2007;
Cejas et al., 2010
Cbl-B Peripheral T cell tolerance Lin and Mak, 2007; Venuprasad, 2010
ITCH (AIP4) T cell tolerance; TH2 development Venuprasad, 2010
GRAIL T cell tolerance; Treg function Nurieva et al., 2010; Anandasabapathy et al., 2003
SOCS proteins T cell maturation, differentiation, and function Alexander and Hilton, 2004; Palmer and Restifo, 2009
B Cells
TRAF2 and 3 B cell development Vallabhapurapu et al., 2008
TRAF6 CD40 signaling; B cell development and TD and TI
responses
Rowland et al., 2007; Kobayashi et al., 2009
A20 (TNFAIP3) B cell tolerance; germinal center selection; CD40 signaling Tavares et al., 2010; Chu et al., 2010
c-IAP-2 GALT B cell homeostasis; noncanonical NF-kB signaling Conze et al., 2010
Act1 B cell survival and tolerance Qian et al., 2004; Qian et al., 2008
Innate Cells
TRAF2 and 5 TNF signaling Micheau and Tschopp, 2003
TRAF3 TLR-mediated IRF3 signaling Oganesyan et al., 2006
TRAF6 TLR signaling Deng et al., 2000
cIAPs TNF signaling Bertrand et al., 2008
ITCH TNF signaling Chang et al., 2006
A20 (TNFAIP3) TNF, TLR, NLR signaling Lee et al., 2000, Boone et al., 2004; Turer et al., 2008;
Hitotsumatsu et al., 2008
TRIM25 RIG-I signaling; type I interferon production Gack et al., 2007
LUBAC TNF, IL-1b signaling Haas et al., 2009; Tokunaga et al., 2009
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they may also help determine the specificity of linkage chain
formation (Ye and Rape, 2009). In addition, many RING E3s
have ubiquitin binding domains (UBDs) that may serve to orient
the acceptor ubiquitin molecule for attack and thereby influence
the type of linkage formed. Indeed, a subset of E3 ubiquitin
ligases, occasionally termed E4 ligases, may preferentially
extend ubiquitin chains on ubiquitinated substrates. Hence, E3
enzymes mediate target recognition and can also contribute to
linkage specificity.
In addition to RING and HECT domain-containing E3 ubiquitin
ligases, other protein motifs, such as plant homology domains
(PHD), U box domains, and a subset of zinc fingers, have been
implicated in E3 ubiquitin ligase activity. The U box, so desig-
nated by the domain found in the yeast ubiquitination factor
UFD2, is amodified RING finger that lacks the canonical cysteine
residues for zinc binding but can nevertheless mediate ubiquitin
ligase activity (Aravind and Koonin, 2000; Hatakeyama et al.,
2001). More recently, a zinc finger motif in the ubiquitin ligase
A20 protein has been shown to mediate E3 ubiquitin ligase
activity (Wertz et al., 2004). Although all proteins bearing such
motifs have not been tested for E3 ubiquitin ligase activity, it is
likely that the number of bona fide E3 ubiquitin ligases will
grow significantly. Moreover, E3 ubiquitin ligases typically
possess the ability to ubiquitinate multiple substrates, suggest-
ing that a significant portion of the mammalian proteome
undergoes ubiquitination.844 Immunity 33, December 22, 2010 ª2010 Elsevier Inc.Ubiquitin Chains of Diverse Conformations Regulate
Immune Signals
Ubiquitination events in immune cells mediate diverse cell
signals and cellular responses. Part of this diversity is due to
the fact that ubiquitin molecules can be attached to proteins as
monomers or as polymers (Figure 1). Monoubiquitination events
regulate DNA repair, receptor endocytosis, vesicle sorting, and
gene silencing (Sigismund et al., 2004). Ubiquitination of DNA
repair proteins can impact immune processes such as class
switch recombination (Li et al., 2010; Santos et al., 2010; Sun
and Chen, 2004). Monoubiquitination has also been implicated
in persistent NF-kB signaling that has implications for human
T cell leukemia virus-1 (HTLV-1) infection and signaling thresh-
olds mediating positive and negative thymic selection (Carter
et al., 2005; Wada et al., 2009; Wang et al., 2010).
Polyubiquitin chains can be formed by using any one of the
seven internal lysine residues (K6, K11, K27, K29, K33, K48,
and K63) or the N-terminal amino group of ubiquitin (Komander,
2009) to form distinct ubiquitin chain linkage types (Figure 1).
Structural studies have revealed that different chain linkages
adopt distinct conformations (Pickart and Fushman, 2004; Fush-
man and Walker, 2010). Hence, distinct chain types could be
distinguished by ubiquitin-dependent proteins.
K48-linked ubiquitin chains that are at least four ubiquitin
molecules in length target misfolded or senescent proteins
for recruitment to the proteasome for proteolytic degradation
(Pickart and Fushman, 2004). In the context of cell signaling,
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Figure 1. A Diverse Array of Ubiquitin Chain Linkages Can Lead to Different Outcomes for the Substrate Protein and Result in Different
Cellular Responses
The colored circles denote monoubiquitin (black) or polyubiquitin chains denoted with various colors corresponding with different linkages, as defined by the
arrows at left. Potential outcomes of substrate proteins conjugated with the given ubiquitin linkage are given in the box at right.
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naling proteins, including both agonists and inhibitors of signal
transduction. Signaling proteins probably do not exhibit the
same biochemical features as misfolded proteins. E3 ubiquitin
ligases that target signaling proteins often recognize modifica-
tions to these proteins that occur during their activation, such
as phosphorylated residues. For example, phosphorylation of
the NF-kB inhibitor IkBa leads to its recognition by a Skp1-
Cul1-F box E3 complex called SCFbTrCP that adds K48 ubiquitin
chains to IkBa and promotes its degradation (Skaug et al., 2009).
Hence, regulated degradation of signaling inhibitors supports
the propagation of canonical NF-kB signals. By contrast, K48
ubiquitination of agonist signaling proteins limits the duration
of signals. An example of this type of ubiquitin regulation is
the negative feedback inhibition of cytokine signaling by sup-
pressors of cytokine signaling (SOCS)-family proteins. SOCS
proteins are E3 ubiquitin ligases that tag cytokine signaling
proteins, such as Janus kinases (JAKs) and cytokine receptors,
with ubiquitin, marking them for degradation (Alexander and Hil-
ton, 2004). Regulated attachment of K48 ubiquitin chains to
agonist signaling molecules has been increasingly recognized
in restricting various immune signaling cascades.
Alternative—non-K48—Ubiquitin Chains Can Target
Modified Proteins for Nonproteolytic Functions
Amajor revelation in cell signaling biology was the discovery that
ubiquitin chains assembled in certain conformations can targetproteins for outcomes other than proteosomal degradation
(Deng et al., 2000; Pickart and Fushman, 2004). Structural
studies showed that K63 ubiquitin chains are more flexible
than K48 chains, providing a biochemical basis for selective
recognition of K63-ubiquitinated proteins (Pickart and Fushman,
2004; Winget and Mayor, 2010; Fushman and Walker, 2010).
A quantitative proteomics profile of polyubiquitin linkages in
yeast showed that all the lysines in ubiquitin can form chains
and, with the exception of lysine 63, can directly target proteins
to the proteasome for degradation with varying efficiency (Xu
et al., 2009b). While ubiquitin chains of distinct conformations
had been defined in yeast, their importance in signaling path-
ways in metazoan organisms is now being more fully realized.
We now highlight some of the recent discoveries that manifest
how the diversity of ubiquitin signaling modalities impact
immune cell signaling pathways.
The presence of four ubiquitin-coding genes and the wide-
spread use of ubiquitin modifications in multiple aspects of cell
biology render strategies for the genetic manipulation of ubiqui-
tin linkages difficult. Chen and colleagues devised a ubiquitin
replacement strategy for testing the requirements for specific
ubiquitin chain linkage in cells. Using an inducible system
for the coordinated knockdown of endogenous ubiquitin and
expression of mutant ubiquitin in model cell lines, they showed
that IL-1-induced NF-kB signaling requires K63 ubiquitin chains.
By contrast, TNF-induced NF-kB signaling can occur in theImmunity 33, December 22, 2010 ª2010 Elsevier Inc. 845
Table 2. NEMO Ubiquitination: Sites, Linkages, Outcomes
Stimulus-Receptor E3 ligase Site of Ub Linkage Outcome Reference
TCR TRAF6 Lys 399 K63 Activation Zhou et al., 2004; Sun and Chen, 2004
Nod2 Lys 285 K63 Activation Abbott et al., 2004
TLR Lys 285, 399 K63 Activation Abbott et al., 2007
LUBAC Lys 285, 309 Linear Activation Tokunaga et al., 2009
Poly I:C, Sendai virus TRIM23 Lys 165, 309, 325, 326, 344 K27 Activation Arimoto et al., 2010
Shigella infection Shigella IpaH9.8 Lys 309, 321 K27 Degradation Ashida et al., 2010
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to show that K63 ubiquitination is required for viral activation
of interferon regulatory factor-3 (IRF3) (Zeng et al., 2010).
These studies and others uncovered the physiological impor-
tance of K63 ubiquitin chains in immune signaling. In addition,
functions of other non-K48 linkages have been described in
immune cells.
K33 Polyubiquitin Chains and TCR Signaling
Like K63 polyubiquitin chains, K33 linkages in yeast are relatively
resistant to proteasomal degradation and may thus support
nondegradative functions (Xu et al., 2009b). K33 linkages have
recently been described in T cells, where the E3 ubiquitin ligases
Cbl-b and Itch appear to cooperatively promote K33-linked
ubiquitination of TCRz. This modification inhibits TCRz’s phos-
phorylation and association with the tyrosine kinase Zap-70
and thereby restricts TCR signaling (Huang et al., 2010). Hence,
K33 ubiquitination can disengage TCRz from TCR signaling
without inducing its proteosomal degradation, providing an addi-
tional mechanism by which ubiquitination can restrict signals.
Utilization of this type of ubiquitin-mediated restriction of signals,
rather than proteosomal degradation, allows cells to reutilize
TCRz without spending energy on degrading and resynthesizing
this protein.
K27 Ubiquitination and IKKg Function
K27-linked ubiquitin chains have been described in several
settings. The E3 ubiquitin ligase TRAF6, which helps build K63
ubiquitin chains, has been reported to promote K6, K27, and
K29 ubiquitination of the Parkinson’s disease proteins DJ-1
and alpha-synuclein, stimulating their accumulation in cyto-
plasmic aggregates (Zucchelli et al., 2010). In the setting of
host-pathogen interactions, two distinct K27 chainmodifications
of the NF-kB regulatory subunit IKKg (also called NEMO) have
been described. During viral infections, the attachment of K27
ubiquitin chains to IKKg by host E3 ubiquitin ligase triparite
motif protein 23 (TRIM23) supports IKKg activation and produc-
tion of antiviral IFN-b (Arimoto et al., 2010). By contrast, during
infection with the bacterium Shigella, the attachment of
K27-linked ubiquitin chains to IKKg by bacterial E3 ubiquitin
ligase IpaH9.8 promotes its degradation and thus suppression
of NF-kB signaling and host defense responses (Ashida et al.,
2010). As bacteria do not possess a ubiquitin conjugation
system, Shigella have apparently hijacked the eukaryotic E3
ubiquitin ligase system to suppress host immune defense mech-
anisms. This exemplifies how pathogens can usurp the ubiquitin
system to affect host signaling cascades (Spallek et al., 2009).
Moreover, these two studies identify K27 ubiquitination of two
distinct lysines of IKKg that lead to two different biochemical
outcomes.846 Immunity 33, December 22, 2010 ª2010 Elsevier Inc.Linear Ubiquitin Chains Are Linked via the N-Terminal
Amino Group
In addition to forming ubiquitin chains by using one of ubiquitin’s
seven lysine residues, so-called ‘‘linear’’ ubiquitin chains can be
built via the N-terminal amino group of ubiquitin. Linear chains
are assembled by an E3 complex called linear ubiquitin chain
assembly complex (LUBAC) (Kirisako et al., 2006), comprising
two E3 ubiquitin ligases, HOIL-1 and HOIP. A ubiquitin-associ-
ated (UBA) domain in HOIP binds to the ubiquitin-like domain
in HOIL-1 to form LUBAC. LUBAC activates the canonical
NF-kB pathway by conjugating linear polyubiquitination chains
to IKKg, and HOIL-1-deficient mouse embryonic fibroblasts
(MEFs) exhibit reduced TNF- or IL-1b-induced IKK kinase
activity (Tokunaga et al., 2009). Hence, linear polyubiquitin
chains appear to be a physiologically important form of ubiquiti-
nation. Of note, linear ubiquitin chains were not detected in
a quantitative yeast proteomic study, so this aspect of the ubiq-
uitin system may have evolved more recently than yeast (Xu
et al., 2009b). Interestingly, the lysines of IKKg that putatively
undergo ubiquitination with linear ubiquitin chains overlap those
identified to undergo K63 ubiquitination. Thus, ubiquitination of
individual lysines on substrate proteins (Table 2) might cross-
regulate ubiquitination of these same lysines by other chains.
Forked Ubiquitin Chains Can Be Formed In Vitro
and In Vivo
Most polyubiquitin chains are believed to be homogenous, i.e.,
contain only one type of isopeptide linkage. Recent studies
have suggested that a proportion of polyubiquitin chains may
be synthesized with mixed linkages, forming forked ubuiquitin
chains (Kirkpatrick et al., 2005, 2006). Forked polyubiquitin
chains are resistant to proteasomal degradation and their for-
mation in the cell can be regulated by association with a ubiqui-
tin-interacting motif (UIM) protein, suggesting that formation of
forked chains may be important in the regulation of normal
protein homeostasis, in the cellular stress response, and/or in
degenerative diseases (Kim et al., 2009).
Unanchored Ubiquitin Chains Support NF-kB Signals
‘‘Anchored’’ ubiquitin chains refer to the typical polyubiquitin
chains that are covalently attached to substrate proteins. ‘‘Unan-
chored’’ polyubiquitin chains, by contrast, are free chains that
are not attached to any substrate. Unanchored chains can be
built by various E3 ubiquitin ligases in vitro. As noted above,
TRAF6 works with the E2 UBC13-UEV1A complex to build
K63-linked ubiquitin chains. These chains are recognized by
the TAK1-TAB1-TAB2 complex, a ubiquitin-dependent kinase
complex that phoshorylates mitogen-activated protein kinase
kinase (MKK) and IkB kinase (IKK)g. A recent study reported
the startling discovery that unanchored K63 ubiquitin chains
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(TAK1) by binding to TAK1 binding protein 2 (TAB2). The pres-
ence of unanchored chains in live cells was uncovered by
treating immunoprecipitated cell lysates with isopeptidase T,
a deubiquitinating enzyme that only cleaves unanchored chains
(because of its requirement for access to the C-terminal carboxyl
group of ubiquitin) (Xia et al., 2009).
Another example of the importance of unanchored chains in
supporting signal transduction was discovered in the retinoic-
acid-inducible gene-1 (RIG-1) pathway. RIG-1-like receptors
(RLRs) are involved in viral recognition and trigger signal trans-
duction cascades leading to type I interferon production, and
TRIM-25 is an E3 ubiquitin ligase required for the activation of
this pathway (Gack et al., 2007). Sequential binding of viral
RNA to RIG-1’s C-terminal regulatory domain and unanchored
K63 ubiquitin chain binding to RIG-1’s N-terminal Caspase
recruiting domain (CARD) may lead to activation of RIG-1
(Zeng et al., 2010). The unanchored K63 chains that bind to
and activate RIG-1 appear to be significantly shorter than the
unanchored chains that bind TAK1. These observations raise
several questions, including whether unanchored chains are
generated as free chains or whether they are cleaved after being
initially built on substrates. If the latter occurs, then additional
enzymatic steps must be required. More globally, how and
why would unanchored chains, rather than anchored chains,
be useful or sufficiently specific in propagating signals? The
answers to these questions should yield surprising insights into
the mechanisms by which ubiquitin chains regulate signals.
In summary, a diverse array of physiological polyubiquitin
chains provides nearly ten-fold-greater biochemical variety
than binary phosphorylation events. These varied polyubiquitin
chains target modified proteins and signaling complexes for
diverse protein-protein interactions such as proteasomal degra-
dation, receptor recycling, signal complex localization, and/or
recruitment of downstream signaling proteins. These interac-
tions help support, restrict, or direct signaling cascades toward
proper cellular responses. Precise construction and utilization
of distinct polyubiquitin chains requires ubiquitin modifying
enzymes that can build, edit, and degrade these chains as well
as ubiquitin sensors that recognize and bind specific chain
types.
Ubiquitin-Modifying Enzymes and Sensors
Deubiquitinating Enzymes Exhibit Chain Specificity
Like phosphorylation, ubiquitination is a reversible process. Over
100 DUBs are predicted to exist in the human proteome. These
enzymes provide an important layer of regulation for ubiquitina-
tion by enzymatically removing ubiquitin chains. Like E2 and E3
ubiquitin ligases, DUBs can exhibit ubiquitin chain specificity.
For example, the DUB Otubain1 is highly specific for cleaving
K48-linked chains (Wang et al., 2009). Meanwhile, the DUB
Cezanne preferentially hydrolyzes K11 ubiquitin chains (Bremm
et al., 2010). In addition to demonstrating chain specificity,
DUBs may be able to remove ubiquitin molecules iteratively
from chains or may cleave entire chains en masse from target
proteins. Several excellent recent reviews have discussed the
varied roles of DUBs in the immune system (Sun, 2008;
Komander et al., 2009; Reyes-Turcu et al., 2009). While this
review will focus on ubiquitin ligases, ligases and DUBs mustbe considered together as coordinated partners in regulating
ubiquitination.
Distinct Ubiquitin Ligases Can Coordinately Modify
Ubiquitination of Individual Proteins
The evidence of chain-specific ubiquitin ligases and DUB
enzymes raise the possibility that individual target proteins
may undergo conjugation with more than one type of ubiquitin
chain, leading to different outcomes. One protein that appears
to undergo ubiquitination with different ubiquitin chain types is
TRAF3. TRAF3 is itself an E3 ubiquitin ligase that is required
for Tir-domain-containing adaptor-inducing interferon b (TRIF)-
dependent type I interferon signaling butmay be a negative regu-
lator of MAPK-dependent proinflammatory responses. TRAF3
undergoes ubiquitination with both K48 and K63 chains down-
stream of the TLR adaptor protein Myd88 and TRIF-mediated
TLR signals (Tseng et al., 2010). When macrophages respond
to LPS, the E3 ubiquitin ligase cIAP1 (or cIAP2) builds K48 ubiq-
uitin chains on TRAF3, leading to its degradation. This allows
MAPK activation and proinflammatory cytokine production. In
contrast, TRIF-dependent signals lead to autoubiquitination
of TRAF3 with K63 ubiquitin chains. This leads to activation of
IRF3 and type I interferon responses. Selective degradation of
cIAP prevents K48 but not K63 ubiquitination of TRAF3. This
differential ubiquitination of TRAF3 inhibits the inflammatory
response without affecting interferon production. These findings
imply that different chain-specific E2 and E3 ubiquitin ligases
regulate TRAF3. Moreover, the selective degradation of cIAP
by the SMACmimetic may have clinical importance for the treat-
ment of inflammatory diseases and cancer.
IKKg has also been described to undergo ubiquitination at
a number of distinct lysines, depending upon the ligands and
E3 ubiquitin ligases involved (Table 2). While most of these
events are thought to lead to IKKg activation, at least one is
thought to lead to proteosomal degradation of IKKg (Ashida
et al., 2010). Hence, conjugation of individual signaling proteins
such as TRAF3, receptor-interacting protein (RIP), and IKKg
with distinct ubiquitin chains regulates the character and
duration of signaling cascades and the attendant biological
responses.
A third example of a signaling protein undergoing conjugation
with two different types of polyubiquitin chains is RIP, a key
mediator of TNF-induced NF-kB signaling. RIP undergoes K63
ubiquitination, probably as a consequence of cIAPs. Ubiquitina-
tion of RIP at lysine 377 is required for the recruitment of the
TAK1-TAB2 complex and IKKg, which in turn leads to phosphor-
ylation of IKKg and IkBa and activation of NF-kB. Interestingly,
RIP also undergoes ubiquitination with K48-linked chains,
leading to RIP’s proteosomal degradation. These K48 chains
are built by A20, which thereby restricts TNF-induced NF-kB
signaling (Wertz et al., 2004). A20-deficient cells exhibit pro-
longed TNF-induced NF-kB signaling (Lee et al., 2000).
DUB and Ubiquitin Ligases Can Coordinately Modify
Ubiquitination of Individual Proteins
How diverse ubiquitination events on individual proteins are
coordinated is poorly understood. One remarkable example
was unveiled by studies of A20’s modifications of RIP. In this
case, A20’s N-terminal half harbors DUB activity, which prefer-
entially degrades anchored K63 chains, while the fourth of its
seven C-terminal zinc fingers (ZF) exhibits E3 ubiquitin ligaseImmunity 33, December 22, 2010 ª2010 Elsevier Inc. 847
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ubiquitin-editing activity is supported by structural data showing
A20 ZF4’s ability to bind monoubiquitin and K63 polyubiquitin
chains, and adjacent ZF5-7 binding to E2 (Bosanac et al.,
2010). The net effect of A20’s dual biochemical activities is to
function as a ubiquitin-editing enzyme, targeting K63-ubqiuiti-
nated RIP molecules and exchanging the K63 chains for K48
chains. In this way, A20 both deactivates and degrades RIP.
While A20 is currently the only protein known to exhibit this
biochemical mechanism of regulating immune signals, it is
intriguing to consider that other examples remain to be discov-
ered, embodied either in single proteins or in higher-order
protein complexes.
Ubiquitin Sensors Can Support or Restrict
Immune Signals
The ability of diverse polyubiquitin chains to trigger different
biochemical outcomes for ubiquitinated substrates implies that
ubiquitin binding proteins, or sensors, must exist that distinguish
these chains. Four ubiquitin sensors have been described to
date to play critical roles in immune signaling. TAB2 and TAB3
use a conserved zinc finger motif to bind K63 ubiquitin chains
on RIP. IKKg, the catalytic subunit of the IKK complex, harbors
a ubiquitin binding domain, termed NUB for Nemo ubiquitin
binding domain, that binds to K63 (Wu et al., 2006; Ea et al.,
2006) and linear ubiquitin chains (Rahighi et al., 2009). Both of
these ubiquitin binding functions are essential for TNF-induced
activation of IKKg. A fourth ubiquitin sensor is called A20 Binding
Inhibitor of NF-kB-1, or ABIN-1. ABIN-1 shares a NUB domain
with IKKg. Unlike TAB2, TAB3, or IKKg, which use their ubiquitin
binding motifs to support TNF-induced NF-kB signaling, ABIN-1
uses its NUB domain to restrict TNF-induced death signaling
(Oshima et al., 2009). While the potential relationship between
ABIN-1’s and IKKg’s NUB domains is currently unclear, these
domain are probably important for modulating the composition
of signaling complexes.
How ubiquitin sensors distinguish between different types of
ubiquitin chains is another important unanswered question. Initial
clues have emerged from biochemical studies of chain-specific
DUBs (Wang et al., 2009). These studies indicate how multipoint
contacts between the K48 chain-specific DUBOtubain1 andK48
ubiquitin chains or between the K63 chain-specific DUB AMSH-
LP and K63 chains determine the specificity of these enzymes
(Wang et al., 2009; Sato et al., 2008). Linkage-specific avidity is
also accomplished by tandem ubiquitin binding sites in the
Rap80 and ataxin 3 ubiquitin sensors (Sims and Cohen, 2009;
Sims et al., 2009). Whether and how tandem ubiquitin binding
motifs may mediate immune signaling remains to be seen.
Together with ubiquitin-modifying enzymes, ubiquitin sensors
complete the core ubiquitin system that regulates immune
signals. Growing appreciation of the biological diverse outcomes
of biochemically distinct ubiquitin chains and of the proteins that
build, bind, and/or degrade these chains provide the biochem-
ical foundations for understanding how diverse ubiquitination
events regulate immune signals.
Immune Functions of E3 Ubiquitin Ligases in Mice
Cell-free biochemistry experiments and cell-line-based studies
suggest that ubiquitin-modifying enzymes and sensors regulate
immune homeostasis and/or immune responses in intact mice.848 Immunity 33, December 22, 2010 ª2010 Elsevier Inc.Mice lacking key components of the ubiquitin machinery, such
as E2 and E3 ubiquitin ligases, provide a means to directly inter-
rogate the in vivo function of individual ubiquitination proteins in
different cellular contexts. The emerging roles of ubiquitination in
innate and adaptive immunity (Table 1) have recently been re-
viewed (Lin and Mak, 2007; Bhoj and Chen, 2009; Skaug et al.,
2009; Wertz and Dixit, 2010). Here, we will focus on selected
gene-targeted mice that have recently been reported and that
illuminate how ubiquitin ligases regulate immune homeostasis,
how ubiquitin-dependent activation and survival signals can be
integrated in specific immune cell types, and how phenotypes
of globally deficient mice represent complex compilations of
lineage-specific functions.
Lineage-Specific Functions of E3 Ubiquitin Ligases
Many E3 ubiquitin ligases are expressed in multiple immune and
nonimmune cell lineages and may regulate multiple pathways.
Thus, complex and often lethal phenotypes result when E3 ubiq-
uitin ligases or associated components of ubiquitination are
globally deleted frommice. Deciphering intrinsic versus extrinsic
phenotypes may be enigmatic—e.g., spontaneously activated
innate immune cells can contribute to T and B lymphocyte
activation, and vice versa. Hence, it is important to test their
physiological roles in a cell-specific context. Lineage-specific
deletions of ubiquitin-modifying enzymes using LoxP-flanked
alleles have recently begun to unveil cell-autonomous functions
for these enzymes in mice. We discuss lineage-specific dele-
tions of the genes encoding TRAF6, A20, and ACT1 to illustrate
the differing roles E3 ubiquitin ligases can play in different cell
types.
Tumor necrosis factor receptor-associated factors (TRAFs)
are important signaling adaptors that can mediate signals from
TNF superfamily receptors (TNFSFR), toll-like (TLR) and inter-
leukin-1 (IL-1R) receptors, and receptor activator of NF-kB
ligand (RANKL) to activate transcription factors NF-kB, NFAT,
Akt, and MAP kinases. Mice deficient for TRAF2, TRAF3, or
TRAF6 die in utero or perinatally from multiple organ abnormali-
ties, demonstrating their nonoverlapping roles in mouse devel-
opment (Ha et al., 2009). TRAF6, the seminal E3 ligase shown
to synthesize nondegradative K63 ubiquitin linkages and acti-
vate NF-kB signaling, is a good example of the divergent func-
tions that one E3 ligase can play in cell-specific contexts. Mice
globally lacking TRAF6 develop osteopetrosis, and Traf6/
fibroblasts exhibit gross defects in IL-1-, LPS-, and CD40-
induced signaling (Lomaga et al., 1999). TRAF6 also supports
NF-kB signals in B cells and dendritic cells (DCs). Mice with
B lineage-specific deletion of Traf6 have impaired B cell matura-
tion, particularly of the B-1a subset, and impaired B2
cell responses to T-dependent and T-independent antigens
(Kobayashi et al., 2009). B cells deficient for both TRAF6 and
TRAF2 exhibit defective CD40 signaling (Rowland et al., 2007).
TRAF6 also appears to have an agonist function inDCmaturation
and development, as judged by chimeric mice bearing Traf6/
hematopoietic cells (Kobayashi et al., 2003). A recent study sug-
gested that TRAF6 autoubiquitination is not required for NF-kB
and MAPK activation in response to IL-1 and RANKL (Walsh
et al., 2008). Thus, TRAF6’s E3 ligase activity may be separable
from its roles in supporting in these signaling pathways.
In contrast to TRAF6’s roles in supporting NF-kB and MAPK
signals, mice lacking TRAF6 specifically in T cells develop
Immunity
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T cell-intrinsic role in preventing spontaneous inflammation.
TRAF-6-deficient T cells are resistant to both induction of
T cell anergy and suppression by regulatory T cells (King et al.,
2006, 2008). They also exhibit an increased propensity to
undergo TH17 differentiation (Cejas et al., 2010). These
surprising phenotypes are hard to reconcile with the known roles
for TRAF6 in supporting activation signals and highlight the fact
that we still understand this protein poorly.
Another E3 ubiquitin ligase with pleiotropic functions is A20.
Mice lacking A20 (Tnfaip3/mice) exhibit multiorgan inflamma-
tion and perinatal death, which is largely, though not completely,
abrogated in Tnfaip3/Myd88/ compound mutant mice (Lee
et al., 2000; Turer et al., 2008). Hence, A20 prevents lethal inflam-
mation by restricting homeostatic MyD88-dependent signals
(Boone et al., 2004; Turer et al., 2008).
A20 restricts both TNF-induced NF-kB signals and TNF-
induced programmed cell death (PCD) signals in fibroblasts
(Lee et al., 2000). Enterocyte-specific deletion of Tnfaip3
(Tnfaip3 Flox Vil1-Cre) causes hypersensitivity to dextran sodium
sulfate (DSS)-induced colitis, which is associated with hypersen-
sitivity of enterocytes to TNF-induced PCD and is partially
rescued by TNFR1 deficiency (Vereecke et al., 2010). By
contrast, B cell-specific loss of A20 surprisingly renders these
cells resistant to PCD mediated by the TNFSFR member Fas.
This resistance is potentially explained by the observation that
A20-deficient B cells are hypersensitive to CD40-triggered
NF-kB signaling, leading to exaggerated Bcl-x expression and
resistance to Fas-mediated PCD. The divergent fashions by
which fibroblasts integrate TNF signals versus how activated B
cell integrate Fas signals highlights the importance of under-
standing cell-type-specific functions of such enzymes. This
lesson is particularly important with proteins such as A20 that
regulate both NF-kB activation signals and PCD signals.
Mice lacking A20 selectively in B cells (Tnfaip3flox/flox Cd19-Cre
mice) also shed light on two important human diseases:
systemic lupus erythematosus (SLE) and B cell lymphoma.
Several single-nucleotide polymorphisms (SNPs) near the
human Tnfaip3 gene are associated with susceptibility to SLE
in genome-wide association studies (GWAS). Tnfaip3flox/flox
Cd19-Cre mice exhibit increased numbers of germinal center
B cells, accumulation of autoreactive B cells, autoantibodies,
and spontaneous SLE-like disease (Tavares et al., 2010; Chu
et al., 2010). These phenotypes are also observed inmice lacking
only one copy of A20 in B cells (Tnfaip3flox/+ Cd19-Cre mice),
demonstrating the biological importance of a full complement
of this potent enzyme. Tnfaip3flox/+ Cd19-Cre mice more closely
resemble the hypomorphic condition likely to occur in SLE
patients bearing germline polymorphisms in the A20 gene.
Meanwhile, somatic deletions and mutation of both A20 alleles
are observed in up to 30% of human B cell lymphomas. Resis-
tance to PCD, due at least in part to the increased expression
of the antiapoptotic Bcl-2 family protein Bcl-x, in A20-deficient
B cells provides a compelling molecular explanation for why
A20 is a prevalent tumor suppressor in human B cells (reviewed
in Malynn and Ma, 2009). As distinct human A20 SNPs are
associated with susceptibilities to other autoimmune and inflam-
matory diseases (e.g., rheumatoid arthritis, psoriasis, celiac
disease), lineage-specific deletion or reduction of A20 expres-sion may provide important insights into the biology underlying
these genetic disease susceptibilities.
Act1, originally identified as an NF-kB activator, was subse-
quently shown to negatively regulate CD40 and BAFF-mediated
B cell survival via its interaction with TRAF3 (Qian et al., 2004).
Act1-deficient (Traf3ip2/) Balb/c mice develop Sjogren
disease associated with lupus-like nephritis (Qian et al., 2008).
In contrast to its role in B cell signaling, Act1 is a positive
signaling regulator of IL-17-mediated responses in T cells by
recruiting TAK1 and TRAF6 (Qian et al., 2007). Act1 possesses
a U box domain and functions as an E3 ubiquitin ligase that
K63 polyubiquinates TRAF6. The ubiquinating activity mediated
by the Act1 U box appears to be required for IL-17-dependent
signaling (Liu et al., 2009). Traf3ip2/ C57BL/6 mice are
resistant to experimentally induced experimental autoimmune
encephalitis (EAE) and inflammatory bowel disease (IBD), due
to reduced expression of proinflammatory cytokines and che-
mokines in astrocytes and gut epithelial cells, respectively
(Qian et al., 2007). The different functions of Act1 in B cells and
T cells may be due to its different binding partners: TRAF3 in
CD40 and BAFF signaling in B cells, and TRAF6 in T cells.
It will be of interest to determine whether Act1’s E3 ubiquitin
ligase activity is also involved in its regulatory activity in B cells.
Future Directions
We are clearly in the very early stages of understanding how
ubiquitination regulates immune signals. Future directions
will probably include identifying the key ubiquitin-modifying
enzymes and sensors that regulate immune signaling cascades.
In this regard, the recognition that most RING-containing
proteins function as E3 ubiquitin ligases occurred as recently
as 1999 (reviewed in Deshaies and Joazeiro, 2009). Bioinfor-
matic analyses predict that over 300 human genes encode
RING domain proteins, and functional evidence of ligase activity
has been obtained for approximately half of them. Some RING
proteins may not have intrinsic ligase activity but are subunits
that enhance the activity of larger complexes. Other RING-like
E3 ubiquitin ligases andHECT ligases bring the number of poten-
tial E3 complexes to over 600. Finally, the recent discoveries of
a zinc finger domain that supports E3 ligase activity (i.e., A20’s
fourth zinc finger) and ubiquitin sensors that support or restrict
TNF signals (e.g., IKKg and ABIN-1) further suggest that addi-
tional biochemically related proteins will be important immune
regulators (Wertz et al., 2004; Oshima et al., 2009; Ea et al.,
2006).
Many of the basic principles and mechanisms of ubiquitin
remain to be elucidated—e.g., how do E2 and E3 enzymes select
each other, how do they build specific types of ubiquitin chains,
and how do they select their substrates? It will be equally impor-
tant to determine how unanchored chains function, how large
ubiquitin-editing complexes are assembled and regulated, how
DUB and ubiquitin ligase functions are coordinated, and how
ubiquitin sensors are integrated into coupled signaling modali-
ties such as kinase activity.
Identifying physiologically relevant ubiquitin chains in immune
cells also poses a challenge. Unlike genetic targeting of ubiqui-
tin-modifying enzymes or sensors, mutating ubiquitin molecules
in the germline will probably lead to early embryonic lethality as
well as rapid and profound cellular adaptation. However,Immunity 33, December 22, 2010 ª2010 Elsevier Inc. 849
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In addition to transient heterologous expression of mutant ubiq-
uitins, semiquantitative mass spectroscopic techniques that
distinguish chain topology have also recently been developed
(Kirkpatrick et al., 2005; Kirkpatrick et al., 2006). Moreover, the
development of antibodies that recognize the epitope formed
by specific ubiquitin linkages should facilitate dissection of ubiq-
uitin bearing signaling complexes in cells (Newton et al., 2008;
Wang et al., 2008;Matsumoto et al., 2010). Combinedwith struc-
tural and biochemical studies and molecular modeling, these
approaches are slowly unveiling clues into how ubiquitin modifi-
cations are used to regulate signaling proteins and cascades
(Winget and Mayor, 2010; Fushman and Walker, 2010).
The potent signaling activities of E3 ubiquitin ligases highlights
the therapeutic potential of manipulating cell activation or cell
death pathways by altering the activity of ubiquitin-conjugating
enzymes (e.g., Scheper et al., 2010). The allure of this area of
drug discovery is enhanced by GWAS and other studies that
implicate genes such as A20 in human autoimmunity and cancer.
The successful development of SMAC mimetics that selectively
induce autoubiquitination of cIAPs and kill cancer cells provides
a tantalizing sample of this small molecule approach (reviewed
in Chen and Huerta, 2009). The Nobel Prize in Chemistry in
2004 was awarded for the discovery of ubiquitin-mediated
degradation of proteins. Six years later, it is clear that we have
only scratched the surface of the complex mechanisms by
which ubiquitination regulates immune signaling and biology.
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